{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:04:58Z","timestamp":1782029098379,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014717","name":"national outstanding youth science fund project of national natural science foundation of china","doi-asserted-by":"publisher","award":["81902584"],"award-info":[{"award-number":["81902584"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009558","name":"university natural science research project of anhui province","doi-asserted-by":"publisher","award":["KJ2019A0280"],"award-info":[{"award-number":["KJ2019A0280"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eukaryotic initiation factor 3a (EIF3A), a \u201creader\u201d protein for RNA methylation, has been found to be involved in promoting tumorigenesis in a variety of cancers. The impact of EIF3A in clear cell renal cell carcinoma (ccRCC) has yet to be reported. This study aimed to identify the prognostic value of EIF3A in ccRCC and investigate the relationship between EIF3A expression and immune infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected 29 m6A-related mRNA data and clinicopathological parameters from The Cancer Genome Atlas (TCGA) database. Logistic regression analyses were used to analyse the correlation between EIF3A expression and clinical characteristics. Immunohistochemistry (IHC) was applied to examine EIF3A levels in normal and ccRCC tissues. Univariate and multivariate analyses were conducted to recognize independent factors associated with overall survival (OS) and disease-free survival (DFS). The nomogram aimed to predict the 1-, 3- and 5-year survival probabilities. Gene set enrichment analysis (GSEA) was carried out to determine the potential functions and related signalling pathways of EIF3A expression. To investigate EIF3A of coexpressed genes, we used LinkedOmics, and the results were subjected to enrichment analysis. Simultaneously, LinkedOmics and STRING datasets were used to identify EIF3A coexpressed genes that were visualized via Cytoscape. Finally, we evaluated whether EIF3A expression correlated with the infiltration of immune cells and the expression of marker genes in ccRCC by Tumour Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>EIF3A expression was significantly different between ccRCC tissues and normal tissues. EIF3A expression was correlated with poor prognostic clinicopathological factors, and K\u2013M analyses revealed that low EIF3A expression was correlated with a poor prognosis. The results of univariate and multivariate analyses proved that EIF3A was a prognostic factor in ccRCC patients. GSEA results indicated that EIF3A high expression was enriched in the renal cell carcinoma pathway. EIF3A expression was significantly positively correlated with B cells, CD8\u2009+\u2009T cells, CD4\u2009+\u2009T cells, neutrophils, macrophages, and dendritic cells. Furthermore, EIF3A expression was associated with most marker genes of immune cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EIF3A could serve as a potential biomarker for prognostic and diagnostic stratification of ccRCC and is related to immune cell infiltrates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12935-021-02364-2","type":"journal-article","created":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:02:38Z","timestamp":1639872158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-0125","authenticated-orcid":false,"given":"Haibing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,19]]},"reference":[{"issue":"5","key":"2364_CR1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/bjc.2016.230","volume":"115","author":"B Greef","year":"2016","unstructured":"Greef B, Eisen T. Medical treatment of renal cancer: new horizons. Br J Cancer. 2016;115(5):505\u201316.","journal-title":"Br J Cancer"},{"issue":"1","key":"2364_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2364_CR3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356\u201387.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2364_CR4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93\u2013105.","journal-title":"Eur Urol"},{"issue":"5","key":"2364_CR5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg B, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799\u2013810.","journal-title":"Eur Urol"},{"issue":"1","key":"2364_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0092-8674(74)90153-6","volume":"1","author":"RP Perry","year":"1974","unstructured":"Perry RP, Kelley DE. Existence of methylated messenger RNA in mouse L cells. Cell. 1974;1(1):37\u201342.","journal-title":"Cell"},{"issue":"10","key":"2364_CR7","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 1974;71(10):3971\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2364_CR8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.cell.2014.08.005","volume":"158","author":"M Lee","year":"2014","unstructured":"Lee M, Kim B, Kim VN. Emerging roles of RNA modification: m(6)A and U-tail. Cell. 2014;158(5):980\u20137.","journal-title":"Cell"},{"issue":"3","key":"2364_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/cr.2017.15","volume":"27","author":"H Shi","year":"2017","unstructured":"Shi H, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315\u201328.","journal-title":"Cell Res"},{"key":"2364_CR10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omtn.2020.08.004","volume":"22","author":"F Dai","year":"2020","unstructured":"Dai F, et al. Crosstalk between RNA m(6)A modification and non-coding RNA contributes to cancer growth and progression. Mol Ther Nucleic Acids. 2020;22:62\u201371.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2364_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12943-019-1033-z","volume":"18","author":"XY Chen","year":"2019","unstructured":"Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103.","journal-title":"Mol Cancer"},{"issue":"21","key":"2364_CR12","doi-asserted-by":"crossref","first-page":"9528","DOI":"10.7150\/thno.42971","volume":"10","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, et al. m(6)A RNA modification modulates PI3K\/Akt\/mTOR signal pathway in gastrointestinal cancer. Theranostics. 2020;10(21):9528\u201343.","journal-title":"Theranostics"},{"key":"2364_CR13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12935-020-01238-3","volume":"20","author":"J Chen","year":"2020","unstructured":"Chen J, et al. Identification of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. Cancer Cell Int. 2020;20:157.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2364_CR14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12935-020-01738-2","volume":"21","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma. Cancer Cell Int. 2021;21(1):46.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"2364_CR15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cell.2015.10.012","volume":"163","author":"KD Meyer","year":"2015","unstructured":"Meyer KD, et al. 5\u2032 UTR m(6)A promotes cap-independent translation. Cell. 2015;163(4):999\u20131010.","journal-title":"Cell"},{"issue":"11","key":"2364_CR16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1054\/bjoc.2001.1828","volume":"84","author":"R Pincheira","year":"2001","unstructured":"Pincheira R, Chen Q, Zhang JT. Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer. 2001;84(11):1520\u20137.","journal-title":"Br J Cancer"},{"issue":"4","key":"2364_CR17","first-page":"1047","volume":"30","author":"J Haybaeck","year":"2010","unstructured":"Haybaeck J, et al. Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res. 2010;30(4):1047\u201355.","journal-title":"Anticancer Res"},{"issue":"3","key":"2364_CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijc.20443","volume":"112","author":"G Chen","year":"2004","unstructured":"Chen G, Burger MM. p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer. 2004;112(3):393\u20138.","journal-title":"Int J Cancer"},{"issue":"4","key":"2364_CR19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13402-014-0181-9","volume":"37","author":"R Spilka","year":"2014","unstructured":"Spilka R, et al. eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr). 2014;37(4):253\u201367.","journal-title":"Cell Oncol (Dordr)"},{"issue":"21","key":"2364_CR20","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1038\/sj.onc.1207465","volume":"23","author":"Z Dong","year":"2004","unstructured":"Dong Z, et al. Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene. 2004;23(21):3790\u2013801.","journal-title":"Oncogene"},{"key":"2364_CR21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3389\/fgene.2019.00439","volume":"10","author":"A Mendoza-Alvarez","year":"2019","unstructured":"Mendoza-Alvarez A, et al. Whole-exome sequencing identifies somatic mutations associated with mortality in metastatic clear cell kidney carcinoma. Front Genet. 2019;10:439.","journal-title":"Front Genet"},{"key":"2364_CR22","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/901956","volume":"2012","author":"R Spilka","year":"2012","unstructured":"Spilka R, et al. Overexpression of eIF3a in squamous cell carcinoma of the oral cavity and its putative relation to chemotherapy response. J Oncol. 2012;2012: 901956.","journal-title":"J Oncol"},{"issue":"13","key":"2364_CR23","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-16-2020","volume":"23","author":"K Chen","year":"2017","unstructured":"Chen K, et al. Alternative splicing of EZH2 pre-mRNA by SF3B3 contributes to the tumorigenic potential of renal cancer. Clin Cancer Res. 2017;23(13):3428\u201341.","journal-title":"Clin Cancer Res"},{"issue":"43","key":"2364_CR24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"D1","key":"2364_CR25","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"Vasaikar SV, et al. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956\u201363.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2364_CR26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/2159-8290.CD-19-0499","volume":"9","author":"L Vuong","year":"2019","unstructured":"Vuong L, et al. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019;9(10):1349\u201357.","journal-title":"Cancer Discov"},{"issue":"6","key":"2364_CR27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson RH, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757\u201361.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2364_CR28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40425-019-0621-1","volume":"7","author":"P Ghatalia","year":"2019","unstructured":"Ghatalia P, et al. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer. 2019;7(1):139.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2364_CR29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2015.03.043","volume":"362","author":"X Zhao","year":"2015","unstructured":"Zhao X, et al. Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett. 2015;362(2):192\u20138.","journal-title":"Cancer Lett"},{"key":"2364_CR30","volume":"10","author":"O Shriwas","year":"2020","unstructured":"Shriwas O, et al. The impact of m6A RNA modification in therapy resistance of cancer: implication in chemotherapy, radiotherapy, and immunotherapy. Front Oncol. 2020;10: 612337.","journal-title":"Front Oncol"},{"issue":"7","key":"2364_CR31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/0008-5472.CAN-18-2965","volume":"79","author":"Q Lan","year":"2019","unstructured":"Lan Q, et al. The critical role of RNA m(6)A methylation in cancer. Cancer Res. 2019;79(7):1285\u201392.","journal-title":"Cancer Res"},{"issue":"56","key":"2364_CR32","doi-asserted-by":"crossref","first-page":"96103","DOI":"10.18632\/oncotarget.21726","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, et al. The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma. Oncotarget. 2017;8(56):96103\u201316.","journal-title":"Oncotarget"},{"key":"2364_CR33","first-page":"5648783","volume":"2019","author":"Q Wang","year":"2019","unstructured":"Wang Q, et al. Identification of METTL14 in kidney renal clear cell carcinoma using bioinformatics analysis. Dis Markers. 2019;2019:5648783.","journal-title":"Dis Markers"},{"key":"2364_CR34","doi-asserted-by":"publisher","DOI":"10.2174\/1574892816666210204125155","author":"J Zhao","year":"2021","unstructured":"Zhao J, Lu L. Interplay between RNA methylation eraser FTO and writer METTL3in renal clear cell carcinoma patient survival. Recent Pat Anticancer Drug Discov. 2021. https:\/\/doi.org\/10.2174\/1574892816666210204125155.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"2364_CR35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.canlet.2017.09.055","volume":"412","author":"JY Yin","year":"2018","unstructured":"Yin JY, et al. eIF3a: a new anticancer drug target in the eIF family. Cancer Lett. 2018;412:81\u20137.","journal-title":"Cancer Lett"},{"issue":"1","key":"2364_CR36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/MCB.05770-11","volume":"32","author":"TR Xu","year":"2012","unstructured":"Xu TR, et al. Eukaryotic translation initiation factor 3, subunit a, regulates the extracellular signal-regulated kinase pathway. Mol Cell Biol. 2012;32(1):88\u201395.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2364_CR37","volume":"8","author":"DJ Lane","year":"2013","unstructured":"Lane DJ, et al. N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS ONE. 2013;8(2): e57273.","journal-title":"PLoS ONE"},{"issue":"4","key":"2364_CR38","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1534\/genetics.104.032656","volume":"168","author":"JW Loar","year":"2004","unstructured":"Loar JW, et al. Genetic and biochemical interactions among Yar1, Ltv1 and Rps3 define novel links between environmental stress and ribosome biogenesis in Saccharomyces cerevisiae. Genetics. 2004;168(4):1877\u201389.","journal-title":"Genetics"},{"issue":"2","key":"2364_CR39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1534\/genetics.106.062117","volume":"174","author":"RM Seiser","year":"2006","unstructured":"Seiser RM, et al. Ltv1 is required for efficient nuclear export of the ribosomal small subunit in Saccharomyces cerevisiae. Genetics. 2006;174(2):679\u201391.","journal-title":"Genetics"},{"issue":"3","key":"2364_CR40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nrc1015","volume":"3","author":"D Ruggero","year":"2003","unstructured":"Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3(3):179\u201392.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2364_CR41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.gde.2011.03.007","volume":"21","author":"CR Stumpf","year":"2011","unstructured":"Stumpf CR, Ruggero D. The cancerous translation apparatus. Curr Opin Genet Dev. 2011;21(4):474\u201383.","journal-title":"Curr Opin Genet Dev"},{"issue":"12","key":"2364_CR42","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1083\/jcb.201804163","volume":"217","author":"JC Collins","year":"2018","unstructured":"Collins JC, et al. Ribosome biogenesis factor Ltv1 chaperones the assembly of the small subunit head. J Cell Biol. 2018;217(12):4141\u201354.","journal-title":"J Cell Biol"},{"issue":"6","key":"2364_CR43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1083\/jcb.201409056","volume":"208","author":"H Ghalei","year":"2015","unstructured":"Ghalei H, et al. Hrr25\/CK1delta-directed release of Ltv1 from pre-40S ribosomes is necessary for ribosome assembly and cell growth. J Cell Biol. 2015;208(6):745\u201359.","journal-title":"J Cell Biol"},{"issue":"318","key":"2364_CR44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac8773","volume":"7","author":"LH Rosenberg","year":"2015","unstructured":"Rosenberg LH, et al. Therapeutic targeting of casein kinase 1delta in breast cancer. Sci Transl Med. 2015;7(318): 318ra202.","journal-title":"Sci Transl Med"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02364-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02364-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02364-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T12:04:14Z","timestamp":1639915454000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02364-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2364"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02364-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-696657\/v1","asserted-by":"object"}]},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"680"}}